Objective: Prophylactic hemofiltration has been reported, in one study, to reduce renal complications and death but necessitates additional up-front health care resource deployment in a critical care setting. We sought to explore the potential scope and cost-effectiveness of this strategy.
A cute renal failure is a frequent complication of intravenous contrast administration, particularly in patients with preexisting chronic kidney disease (CKD) and diabetes (1) (2) (3) (4) (5) 6) . It is estimated that in excess of 1 million procedures using contrast media are performed annually in the United States, with 150,000 cases of contrast nephropathy occurring per year (2, 7, 8) . In addition to prolonging hos-pitalization (9 -11) , contrast nephropathy may necessitate temporary or permanent dialysis and may independently increase the risk of mortality (11) . Although the overall fraction of patients at very high risk is reported to be small ‫,)%2ف(‬ their risk of acute in-hospital dialysis is high, at 13% (12) . These adverse clinical and economic outcomes have led to investigation of preventive strategies.
A recent randomized trial studied the use of prophylactic hemofiltration in an intensive care setting for those at high risk of developing contrast induced acute renal failure (13) . Periprocedural hemofiltration reduced the incidence of contrast nephropathy, need for subsequent dialysis, and mortality when compared with saline infusion. However, implementation of this strategy necessitates the use of limited critical care resources and considerable expense, and the costeffectiveness is unknown (8, 14, 15) .
Decision analysis allows examination of how uncertainty in important factors, such as the uncertainty regarding the true effectiveness of hemofiltration, influences cost-effectiveness (16, 17) . This is important for defining the potential scope of a new but costly intervention and to guide future research so that outcomes critical to decision-making regarding implementation and the role of new treatment can be measured (18) . In this economic evaluation, we explored the cost-effectiveness of hemofiltration, compared with saline infusion, to prevent contrast nephropathy in high-risk subjects on the basis of effectiveness data from a recent randomized trial (13) . We identified parameters to which the results were sensitive in order to assist decisionmaking regarding use of this strategy, which if implemented would have significant implications to practices within the critical care setting. Because the use of the most appropriate comparator is important in this type of analysis (17) , hemofiltration was also compared with sodium bicarbonate infusion (19) as well as <265 mol/L). The cost-effectiveness remained <$50,000/QALY provided that the relative risk of hemofiltration compared with saline alone was below 0.65 (reported relative risk, 0.10). Although based on indirect comparison of clinical efficacy, when N-acetylcysteine or sodium bicarbonate was used as the comparator, the cost per QALY gained for hemofiltration became markedly less attractive ($50,100 and >$1,000,000), although the relative effectiveness of these three strategies strongly influenced the results.
Conclusions: Use of prophylactic hemofiltration in patients at high risk for contrast nephropathy may be potentially cost-effective only if certain conditions are satisfied, and its attractiveness is materially diminished when compared to other strategies. As this invasive therapy would entail certain immediate resource outlay, before considering its implementation it is crucial to confirm the clinical effectiveness and health care resource consequences of hemofiltration relative to current standards of care in future studies. (Crit Care Med 2006; 34:1044-1051) KEY WORDS: costs and cost analysis; kidney failure; hemofiltration; contrast media; decision support techniques saline infusion with N-acetylcysteine, as both are considered by some to represent the standard of care (8, 20, 21) .
METHODS
A decision analytic model was constructed incorporating costs and outcomes of strategies to prevent contrast nephropathy in a high-risk population receiving low-osmolality intravenous contrast material at doses typically required for coronary angiography, based primarily on the randomized study by Marenzi et al. (13) . The cohort studied in the base case was at high risk for contrast nephropathy, as defined by an average serum creatinine level of 265 mol/L, an average age of 70 yrs, and a high prevalence of coronary artery disease. The base case analysis considered the perspective of a third-party payer over a 1-yr time frame. The discounting of effects and costs occurring in the future (16) was not performed, given the short time frame. Data for the model were obtained from literature sources, with effectiveness data primarily based on the Marenzi et al. study (13) , and both one-way and multiway sensitivity analyses were performed. Because this analysis incorporated data from published sources but did not involve direct study of human participants, ethics review at the University of Alberta was not required.
Preventive Strategies. In the primary analysis, prophylactic hemofiltration was compared with intravenous saline, as previously described by Marenzi et al. (13) . The hemofiltration strategy consisted of admission to an intensive care unit and provision of hemofiltration through a femoral catheter at 1000 mL/min for 4 to 6 hrs before the procedure and then for 18 -24 hrs after the procedure. The saline infusion strategy consisted of admission to a step-down care unit for 4 -6 hrs for intravenous saline before the procedure and 24 hrs after at a dosage of 0.5 to 1 mL/kg/ hr, depending on ejection fraction. In secondary models, hemofiltration as described was compared with infusion of sodium bicarbonate instead of saline, as well as saline infusion with 600 mg of N-acetylcysteine given twice daily for 24 hrs before and after the procedure. Although sodium bicarbonate and N-acetylcysteine have not been directly compared with hemofiltration, both may reduce the incidence of contrast nephropathy (19, (22) (23) (24) (25) and are inexpensive and relatively convenient to administer (8) . The relative risk of contrast nephropathy and 95% confidence intervals of these strategies were obtained from a randomized controlled trial of hemofiltration vs. intravenous saline (13), a randomized trial of sodium bicarbonate vs. sodium chloride (19) , and meta-analyses comparing saline infusion with and without N-acetylcysteine (22-25) ( Table 1) .
Decision Model. The structure of the model and the preventive strategies examined are shown in Figure 1 . After the administration of contrast material, subjects are at risk of developing various renal complications (e.g., contrast nephropathy or the need for dialysis) and/or death, as shown. Long-term outcomes for survivors were modeled by a Markov process, consisting of health states of CKD with cardiovascular disease, end-stage renal disease, and death. A thorough literature search was performed with use of electronic databases, hand searches of pertinent journals, review of bibliographies, and search of personal files to obtain model parameters. Contrast nephropathy was defined as a rise in the serum creatinine level of 25% or more, an operational definition commonly reported in the literature.
Prevalence of Contrast Nephropathy and Need for Dialysis. In the primary analysis, the probability of developing acute renal failure and subsequent need for dialysis was that observed from the Marenzi et al. randomized 
ESRD, end-stage renal disease; CKD, chronic kidney disease; CI, confidence interval; CCU, chronic care unit. a Additional sensitivity analysis evaluated a wider range.
trial (13) . The probability of renal recovery for those requiring dialysis was not directly reported in this study, and complete recovery of renal function was conservatively assumed, favoring the saline infusion strategy. Renal recovery rates reported from other studies involving a similar high-risk group of patients were explored in a sensitivity analysis (2) (3) (4) . The analysis was repeated in subgroups of patients with a lower risk for development of renal complications. Mortality. Development of contrast nephropathy is associated with a marked increase in short-term mortality (1-3, 5, 11, 26 -28), with observational and interventional studies suggesting that strategies that prevent contrast nephropathy may reduce mortality (11, 13) . We used two methods to model mortality. In the primary analysis, we used the mortality rate by renal outcome as reported in observational and clinical trials (Table 1) . Thus, reduction in renal complications with institution of any preventive strategy would reduce the associated risk of mortality in the model. A second method used data from the only randomized controlled trial that reported a mortality benefit, which was ascribed to the use of hemofiltration (13) . The two methods were compared, which served to validate the model. Long-term mortality estimates were based on the United States Renal Data System for those with end-stage renal disease (29) and on subjects with CKD and a high prevalence of cardiovascular disease (30, 31) . Age-specific mortality rates were based on an average patient age of approximately 70 yrs (2) (3) (4) 13) .
Quality of Life.
Age-specific quality-of-life estimates, expressed as utility scores for use in economic analysis, were obtained for the short-and long-term clinical states considered within the model from subjects similar to the cohort of interest, namely, elderly subjects after revascularization for coronary ischemia (32) . Utility estimates for those requiring dialysis were based on average scores from hemodialysis patients (33, 34) , with scores from subjects with coexisting comorbidity incorporated in the sensitivity analysis to account for coexisting cardiovascular disease. Further sensitivity analysis was performed over a plausible range based on other literature sources ( Table 1) . A secondary analysis evaluated life expectancy only.
Resource Use. Resources utilized for each preventive strategy were based on the description given in the study report of Marenzi et al. (13) , including time spent in various care settings such as the intensive care and step-down unit, duration of hemofiltration, as well as additional resources used by those in the hemofiltration groups who developed complications. Additional resource use for subjects who developed complications (including need for dialysis) were taken from other published sources (1-6, 9 -11, 13, 19, 26 -35) (Table 1) . Unit costs for each resource were taken from literature sources or local cost data (36 -42) ( Table 2 ). All costs were adjusted to 2003 United States dollars (U.S. $1 ϭ CAN $1.40 ϭ Euro 0.885).
Given that many intensive care settings are running at maximum capacity (43), we esti-mated the capital costs of expanding the intensive care at our own quaternary care setting to provide prophylactic hemofiltration ($2,712 per m 2 , with an additional 35% for architectural and engineering fees, legal fees, building permits, etc., and $17,844 per room for equipment), including additional hemofiltration equipment ($27,124) . The lifespan of this capital was conservatively estimated to be 4 yrs, and a cost per patient was conservatively assigned on the basis of a 250-days-per-year operation, a commitment of 3 days for each subject with this strategy, and working at 50% of capacity. These conservative assumptions favor saline infusion over hemofiltration.
Analysis. The principal analysis performed was of cost-effectiveness, expressed as the incremental cost per quality-adjusted life-year (QALY) gained. Because some consider an intervention with a cost-effectiveness ratio of Ͻ$50,000/QALY to be potentially economically attractive but Ͼ$100,000/QALY to be weak evidence for adoption, these thresholds were used as reference (44, 45) .
Sensitivity Analysis. One-way deterministic sensitivity analysis was performed over the plausible range for each variable in one-way sensitivity analysis (Tables 1 and 2) . Specific parameters were evaluated in greater detail, including the relative benefit of hemofiltration compared with intravenous saline, the average baseline risk of developing contrast nephropathy, and the probability of the need for temporary and permanent dialysis should contrast nephropathy occur. We also examined the scenario in which saline administration was performed in the ward setting, as opposed to a step-down unit. Finally, hemofiltration was compared with administration of sodium bicarbonate as well as N-acetylcysteine with saline infusion.
Using Markov processes, we extended the time frame over patient lifetime, using attributable mortality due to CKD and end-stage renal disease (29, 30) in conjunction with agespecific mortality rates. For this extended time frame a discount rate of 3% per annum for future costs and benefits was used (16) . All analyses were performed with decision analysis software (Pro Suite 2004, 7.5, TreeAge Software, Williamstown, MA).
RESULTS

Validity of Model in Comparison with
Clinical Trial Data. We assessed the validity of the model by comparing modelpredicted mortality for a given probability of developing contrast nephropathy with randomized trial data. In the primary analysis, the in-hospital mortality predicted by the model was 14.3% for saline infusion and 1.8% for hemofiltration, which is similar to the observed mortality of 14.0% and 1.7% reported by Marenzi et al. (13) . At 1 yr, model-predicted and observed mortality was 30.0% and 30.0% for the intravenous saline group and 17.2% and 10% for the hemofiltration group. The fraction of subjects receiving chronic renal replacement therapy at 1 yr was 1.9% for both model-predicted and observed values in the hemofiltration group and 2.8% vs. 5.4% in the control group. Compared with observed results, the higher 1-yr mortality in the hemofiltration group and lower fraction receiving dialysis in the control group in the model would favor the saline strategy.
Budget Impact Analysis. The estimated cost of providing hemofiltration was calculated at $4480 per patient. Given that this strategy can be provided at only a facility level, the estimated cost for hemofiltration over 4 yrs for 40 highrisk patients treated in this manner is $720,000 per institution. The incremental costs of this treatment are $285,000 in comparison with saline in the step-downunit setting or $539,200 in comparison with saline in a ward setting. As noted below, some of these costs may be offset by savings in other areas (e.g., a reduction in the need for subsequent hemodialysis for acute renal failure).
Hemofiltration vs. Saline Infusion. In the base case, periprocedural hemofiltration was associated with an incremental cost of US$3,900 per QALY gained when compared with the intravenous saline strategy ( Table 3 ). Extending the time frame to patient lifetime reduced the cost-effectiveness ratio to $1400/QALY. One-way sensitivity analysis did not lead to a cost-effectiveness ratio exceeding $50,000/QALY for any parameter examined (Table 3) , although it did result in scenarios where hemofiltration was dominant (that is, less costly and more effective than intravenous saline). However, a Dominant indicates that the strategy referred to is more effective and less costly than the comparator strategy; b using the lower range for ward day costs for the step-down unit represents a scenario where saline is administered in a ward setting (the lowest plausible cost); c the time frame of the analysis extends until 99.9% of simulated patients have entered the "dead" state (Ͻ0.01% surviving). several parameters resulted in a several-fold increase in the cost per unit of benefit achieved, including the per diem costs, total cost of hemofiltration, and fraction of subjects who experienced complications in the hemofiltration group. The results of our analysis were not sensitive to changes in the method used to model mortality, plausible variation in the duration of hemodialysis for acute renal failure, risk of progression from CKD to endstage renal disease, or estimate used for quality of life. Using survival rather than QALY as the effectiveness outcome did not influence the interpretation of the results ($2600 per life-year).
Because the protective effect of hemofiltration has been revealed in only one study and, therefore, the efficacy is not known with certainty, the consequences of varying the relative risk of contrast nephropathy with hemofiltration within its 95% confidence interval was also examined (Table 1) . Compared with saline, the cost per QALY gained became higher than $50,000 and $100,000 per QALY gained when the relative risk of contrast nephropathy with hemofiltration ex-ceeded 0.65 and 0.79, compared with the calculated relative risk of 0.10 (95% confidence interval, 0.03-0.32) (13) .
The risk of developing contrast nephropathy and subsequent need for dialysis therapy were varied in order to explore the expected incremental costeffectiveness of hemofiltration compared with saline in populations with varying baseline risk of developing contrast nephropathy, as defined by published reports (Table 4 ). Although several of these studies enrolled "high-risk patients" (3, 4) , if the actual risk of developing renal complications was low, a much less favorable cost-effectiveness ratio resulted.
Hemofiltration vs. Sodium Bicarbonate and N-acetylcysteine. Secondary models considered the use of sodium bicarbonate as well as N-acetylcysteine with saline infusion for the prevention of contrast nephropathy. The cost-effectiveness ratio of hemofiltration vs. sodium bicarbonate infusion was in excess of $1,000,000/ QALY. When the relative risk of contrast nephropathy for sodium bicarbonate was varied within its calculated 95% confidence interval, hemofiltration was asso-ciated with a cost-effectiveness ratio of $50,000/QALY and $100,000/QALY when the relative risk with sodium bicarbonate was 0.65 and 0.58, respectively, compared with the reported relative risk of 0.12 (95% confidence interval, 0.02-0.95). When the relative risk with hemofiltration was set at the upper 95% confidence limit (0.32), the threshold of $50,000/ QALY or less was achieved when the relative risk with sodium bicarbonate was 0.65 or greater ( Table 5 ). The expected occurrences of contrast nephropathy, dialysis, and death with saline, sodium bicarbonate, N-acetylcysteine, and hemofiltration are also presented in Table 5 . For the high-risk cohort examined, hemofiltration may be a reasonable strategy only if it prevents 17 to 18 cases of contrast nephropathy or 7 to 9 cases of dialysis when compared with sodium bicarbonate, for every 100 patients undergoing contrast procedures.
DISCUSSION
Currently the potential scope of prophylactic hemofiltration to prevent contrast nephropathy is unclear because of uncertainty about implications for healthcare resource use, as well as its true effectiveness in various at-risk populations (8, 20) . We have used information from a randomized trial of hemofiltration with the best available data from other literature sources to evaluate the potential cost-effectiveness of this resource-intensive treatment. This evaluation provides greater clarity as to what variables influence the cost-effectiveness of hemofiltration and hence what infor- CN, contrast nephropathy; RR, relative risk; HF, hemofiltration; NAC, N-acetylcysteine. a RR of CN with HF, 0.10 (base case); b RR of CN with HF and sodium bicarbonate, 0.10 and 0.12, respectively (base case); c RR of CN for sodium bicarbonate for $50,000/QALY threshold for given RR with HF; d RR of CN for NAC, 0.44 (base case). The calculated 95% confidence intervals for the relative risk of contrast nephropathy are 0.10 (0.03-0.32) for hemofiltration and 0.12 (0.02-0.95) for sodium bicarbonate are used to explore the possible cost-effectiveness ratios, including reference to the $50,000/QALY threshold. mation should be determined with greater certainty before scarce critical care resources are used for this strategy. Our analysis suggests that there may be a potential future role for this strategy only if certain conditions are met, even at lower levels of effectiveness than reported by Marenzi et al. (13) . However, given that the use of hemofiltration will involve some risk to patients and certain resource outlay, further study is mandatory.
Although hemofiltration was consistently associated with acceptable costeffectiveness ratios when compared with intravenous saline, its economic attractiveness was materially altered by comparison with sodium bicarbonate and N-acetylcysteine. Whereas the apparent efficacy of sodium bicarbonate and N-acetylcysteine is lower than that reported with hemofiltration, at least on the basis of "indirect" comparisons, their very low incremental resource use makes their administration an appealing strategy. However, the costs and benefits attributable to both sodium bicarbonate and N-acetylcysteine use must be interpreted with several caveats. Although a reduction in hospital stay has been reported with use of N-acetylcysteine in one trial (46) , most trials use the surrogate outcome of percentage rise in serum creatinine, and no studies have documented a reduction in mortality or the need for dialysis.
It is also important to note that the populations studied are of varying risk; it is unknown if sodium bicarbonate would achieve similar effectiveness in a higherrisk cohort such as that in the hemofiltration study. We assumed that the reduction in adverse renal outcomes (e.g., a 25% rise in serum creatinine) with use of sodium bicarbonate and N-acetylcysteine would lead to a reduction in mortality, similar to that reported for hemofiltration. However, this may not be true, in which case the cost-effectiveness ratio of hemofiltration vs. N-acetylcysteine or sodium bicarbonate is likely to be more attractive.
A similar criticism regarding the surrogate marker of serum creatinine could also be applied to hemofiltration, as the primary end point in the study of Marenzi et al. (13) also used changes in this marker as a primary outcome. Our mathematical model does not utilize a rise in serum creatinine as a measure of effectiveness, but it is incorporated to define the probability of developing complications and mortality (Table 1) , and therefore if hemofiltration reduced the devel-opment of contrast nephropathy but not other associated complications, it would overestimate the true effectiveness of hemofiltration. We explored this by comparing model-predicted mortality, which is based on mortality estimates from sources other than the Marenzi study (13) , with that reported in the trial, which did not appreciably alter the results.
The marked change in the costeffectiveness ratio when a strategy using N-acetylcysteine or sodium bicarbonate is considered demonstrates the importance of using the most appropriate comparator (16, 17) . Analysis of the uncertainty in the effectiveness of these three strategies by exploring expected outcomes through the 95% confidence intervals demonstrates that there may be a plausible costeffective role for hemofiltration. At the upper end of the 95% confidence interval for hemofiltration (0.32), it would be below the arbitrary threshold of $50,000/ QALY if it prevents 18 of the expected 33 cases of contrast nephropathy when the relative risk of contrast nephropathy is 0.65, which is within its calculated 95% confidence interval. We suggest that future trials in this area should include the use of sodium bicarbonate or another relatively inexpensive and effective method as the comparator strategy.
The population studied by Marenzi et al. (13) was composed of very-high-risk subjects, with 50% developing renal contrast nephropathy, and 50% of subjects in the control arm required acute dialysis. Other studies recruiting high-risk subjects (3, 4) revealed a lower rate of observed renal complications, which has a substantial impact on the cost-effectiveness of this therapy as well as the number of patients who may potentially be treated in a given center. Our results indicate that this strategy would not be appropriate for low-risk or even moderate-risk patients, which comprise the majority of at-risk patients.
The model assumes that prevention of contrast nephropathy would directly reduce morbidity and mortality, independent of comorbidities that may predispose to both acute renal failure and subsequent complications. Previously published literature supports this assumption (11) , including the reduction in in-hospital mortality observed in a randomized trial (13) . In this latter study, the deaths that occurred were between 3 and 14 days after the intervention, and 75% of the deaths in the control group were of those with acute renal failure (14) . These findings are also consistent with the hypothesis that preventing acute renal failure would reduce the occurrence of other deleterious clinical outcomes. Future emergence of higher-quality evidence, especially regarding the relationship between prevention of contrast nephropathy and mortality, may necessitate modification of this model. Several limitations deserve mention. First, the relative risk of contrast nephropathy with hemofiltration is based on only one randomized trial, and two other trials evaluating periprocedural hemodialysis have not demonstrated any benefit (4, 47) . Hemodialysis is effective in removing contrast media (48 -51) , and the rationale for why hemofiltration but not hemodialysis may be effective is unclear. However, sensitivity analysis suggests that hemofiltration may be cost-effective even at lower levels of effectiveness than reported (relative risk of 0.65 vs. the reported relative risk of 0.10). Second, the data regarding resources used and the costs were obtained from literature sources rather than direct measurements. If the reduction of contrast nephropathy is not associated with a concomitant decrease in hospital stay in the high-risk population under study, the results may be materially different. It was also assumed that patients would accept any therapeutic strategy that would improve outcomes, but patients' preferences with respect to undergoing the invasive procedure of hemofiltration in a critical care setting, including exposure to the small risk associated with the use of a central line, were not determined. Finally, the potential impact on subjects who are currently denied procedures involving contrast because they are deemed to be at too high of risk but who may have an acceptable risk with effective therapy was not examined here. The cost-effectiveness for this group of subjects is likely to be very different that that explored here.
In conclusion, we used the best available data to perform a preliminary costeffectiveness analysis of hemofiltration to define its potential future scope and to identify key parameters where further research is required (18) . If the assumption that hemofiltration prevents acute renal failure proves to be correct, our findings suggest that implementation of this strategy in high-risk patients may be costeffective if certain conditions are met, but it is likely to be attractive in only a small fraction of patients at high risk of con-trast nephropathy. Furthermore, the effectiveness of hemofiltration relative to other strategies such as use of sodium bicarbonate or N-acetylcysteine has not yet been established. Given that this therapy is invasive and its use would entail certain immediate resource outlay and a dramatic change in practice in the critical care setting, it is crucial to confirm in future trials the clinical benefits of hemofiltration relative to current standards of care. Trials involving the collection of detailed information regarding patient outcomes and costs must be performed before the use of prophylactic hemofiltration can be considered.
